Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 663

1.

The National MDS Natural History Study: design of an integrated data and sample biorepository to promote research studies in myelodysplastic syndromes.

Sekeres MA, Gore SD, Stablein DM, DiFronzo N, Abel GA, DeZern AE, Troy JD, Rollison DE, Thomas JW, Waclawiw MA, Liu JJ, Al Baghdadi T, Walter MJ, Bejar R, Gorak EJ, Starczynowski DT, Foran JM, Cerhan JR, Moscinski LC, Komrokji RS, Deeg HJ, Epling-Burnette PK.

Leuk Lymphoma. 2019 May 21:1-11. doi: 10.1080/10428194.2019.1616186. [Epub ahead of print]

PMID:
31111762
2.

Total body irradiation dose and risk of subsequent neoplasms following allogeneic hematopoietic cell transplantation.

Baker KS, Leisenring WM, Goodman PJ, Ermoian RP, Flowers ME, Shoch G, Storb R, Sandmaier BM, Deeg HJ.

Blood. 2019 Apr 16. pii: blood.2018874115. doi: 10.1182/blood.2018874115. [Epub ahead of print]

PMID:
30992266
3.

Pre-hematopoietic cell transplant Ruxolitinib in patients with primary and secondary myelofibrosis.

Salit RB, Scott BL, Stevens EA, Baker KK, Gooley TA, Deeg HJ.

Bone Marrow Transplant. 2019 Apr 8. doi: 10.1038/s41409-019-0523-3. [Epub ahead of print]

PMID:
30962501
4.

Outcomes of Patients With Therapy-Related MDS After Chemoimmunotherapy for Chronic Lymphocytic Leukemia Compared With Patients With De Novo MDS: A Single-Institution Experience.

Cooper JP, Khajaviyan S, Smith SD, Maloney DG, Shustov AR, Warren EH, Soma LA, Lynch RC, Ujjani C, Till B, Halpern AB, Gopal AK, Deeg HJ, Scott BL, Shadman M.

Clin Lymphoma Myeloma Leuk. 2019 Mar 11. pii: S2152-2650(19)30124-7. doi: 10.1016/j.clml.2019.03.003. [Epub ahead of print]

PMID:
30948330
5.

Asymmetric dimethylarginine - a prognostic marker for transplant outcome?

Woo J, Deeg HJ.

Haematologica. 2019 Apr;104(4):646-647. doi: 10.3324/haematol.2018.212191. No abstract available.

6.

Total body irradiation dose escalation decreases risk of progression and graft rejection after hematopoietic cell transplantation for myelodysplastic syndromes or myeloproliferative neoplasms.

Monaco F, Scott BL, Chauncey TR, Petersen FB, Storer BE, Baron F, Flowers ME, Deeg HJ, Maloney DG, Storb R, Sandmaier BM.

Haematologica. 2019 Jun;104(6):1221-1229. doi: 10.3324/haematol.2018.199398. Epub 2019 Jan 10.

7.

Impact of Body Mass Index on Outcomes of Hematopoietic Stem Cell Transplantation in Adults.

Doney K, McMillen K, Buono L, Deeg HJ, Gooley T.

Biol Blood Marrow Transplant. 2019 Mar;25(3):613-620. doi: 10.1016/j.bbmt.2018.10.006. Epub 2018 Oct 10.

PMID:
30315943
8.

More than one angle to target aplastic anemia?

Deeg HJ.

Cancer. 2018 Nov 1;124(21):4165-4167. doi: 10.1002/cncr.31656. Epub 2018 Oct 11. No abstract available.

PMID:
30307607
9.

Allogeneic Hematopoietic Cell Transplantation in Patients Aged 50Years or Older with Severe Aplastic Anemia.

Rice C, Eikema DJ, Marsh JCW, Knol C, Hebert K, Putter H, Peterson E, Deeg HJ, Halkes S, Pidala J, Anderlini P, Tischer J, Kroger N, McDonald A, Antin JH, Schaap NP, Hallek M, Einsele H, Mathews V, Kapoor N, Boelens JJ, Mufti GJ, Potter V, Pefault de la Tour R, Eapen M, Dufour C.

Biol Blood Marrow Transplant. 2019 Mar;25(3):488-495. doi: 10.1016/j.bbmt.2018.08.029. Epub 2018 Sep 5.

PMID:
30194027
10.

Hematopoietic cell transplant for acute myeloid leukemia and myelodysplastic syndrome: conditioning regimen intensity.

Eapen M, Brazauskas R, Hemmer M, Perez WS, Steinert P, Horowitz MM, Deeg HJ.

Blood Adv. 2018 Aug 28;2(16):2095-2103. doi: 10.1182/bloodadvances.2018021980.

11.

Transplant Conditioning with Treosulfan/Fludarabine with or without Total Body Irradiation: A Randomized Phase II Trial in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia.

Deeg HJ, Stevens EA, Salit RB, Ermoian RP, Fang M, Gyurkocza B, Sorror ML, Fatobene G, Baumgart J, Burroughs LM, Delaney C, Doney K, Egan DN, Flowers MED, Milano F, Radich JP, Scott BL, Sickle EJ, Wood BL, Yeung C, Storer BE.

Biol Blood Marrow Transplant. 2018 May;24(5):956-963. doi: 10.1016/j.bbmt.2017.12.785. Epub 2017 Dec 20.

12.

Impact of copy neutral loss of heterozygosity and total genome aberrations on survival in myelodysplastic syndrome.

Yeung CCS, McElhone S, Chen XY, Ng D, Storer BE, Deeg HJ, Fang M.

Mod Pathol. 2018 Apr;31(4):569-580. doi: 10.1038/modpathol.2017.157. Epub 2017 Dec 15.

13.

Transplant Decisions in Patients with Myelofibrosis: Should Mutations Be the Judge?

Salit RB, Deeg HJ.

Biol Blood Marrow Transplant. 2018 Apr;24(4):649-658. doi: 10.1016/j.bbmt.2017.10.037. Epub 2017 Nov 8. Review.

14.

Hematopoietic Cell Transplantation for Myelofibrosis: the Dynamic International Prognostic Scoring System Plus Risk Predicts Post-Transplant Outcomes.

Samuelson Bannow BT, Salit RB, Storer BE, Stevens EA, Wu D, Yeung C, Fang M, Petersdorf EW, Linenberger ML, Woo J, Sorror ML, Doney K, Sandmaier BM, Deeg HJ, Scott BL.

Biol Blood Marrow Transplant. 2018 Feb;24(2):386-392. doi: 10.1016/j.bbmt.2017.09.016. Epub 2017 Sep 29.

15.

Epigenetically Aberrant Stroma in MDS Propagates Disease via Wnt/β-Catenin Activation.

Bhagat TD, Chen S, Bartenstein M, Barlowe AT, Von Ahrens D, Choudhary GS, Tivnan P, Amin E, Marcondes AM, Sanders MA, Hoogenboezem RM, Kambhampati S, Ramachandra N, Mantzaris I, Sukrithan V, Laurence R, Lopez R, Bhagat P, Giricz O, Sohal D, Wickrema A, Yeung C, Gritsman K, Aplan P, Hochedlinger K, Yu Y, Pradhan K, Zhang J, Greally JM, Mukherjee S, Pellagatti A, Boultwood J, Will B, Steidl U, Raaijmakers MHGP, Deeg HJ, Kharas MG, Verma A.

Cancer Res. 2017 Sep 15;77(18):4846-4857. doi: 10.1158/0008-5472.CAN-17-0282. Epub 2017 Jul 6.

16.

Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q).

Fenaux P, Giagounidis A, Selleslag D, Beyne-Rauzy O, Mittelman M, Muus P, Nimer SD, Hellström-Lindberg E, Powell BL, Guerci-Bresler A, Sekeres MA, Deeg HJ, Del Cañizo C, Greenberg PL, Shammo JM, Skikne B, Yu X, List AF.

J Hematol Oncol. 2017 Jun 26;10(1):131. doi: 10.1186/s13045-017-0491-2.

17.

Allogeneic Hematopoietic Cell Transplantation Using Treosulfan-Based Conditioning for Treatment of Marrow Failure Disorders.

Burroughs LM, Shimamura A, Talano JA, Domm JA, Baker KK, Delaney C, Frangoul H, Margolis DA, Baker KS, Nemecek ER, Geddis AE, Sandmaier BM, Deeg HJ, Storb R, Woolfrey AE.

Biol Blood Marrow Transplant. 2017 Oct;23(10):1669-1677. doi: 10.1016/j.bbmt.2017.06.002. Epub 2017 Jun 7.

18.

Hematopoietic Cell Transplantation in Myelodysplastic Syndromes after Treatment with Hypomethylating Agents.

Festuccia M, Baker K, Gooley TA, Sandmaier BM, Deeg HJ, Scott BL.

Biol Blood Marrow Transplant. 2017 Sep;23(9):1509-1514. doi: 10.1016/j.bbmt.2017.05.034. Epub 2017 Jun 30.

19.

Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes.

Scott BL, Pasquini MC, Logan BR, Wu J, Devine SM, Porter DL, Maziarz RT, Warlick ED, Fernandez HF, Alyea EP, Hamadani M, Bashey A, Giralt S, Geller NL, Leifer E, Le-Rademacher J, Mendizabal AM, Horowitz MM, Deeg HJ, Horwitz ME.

J Clin Oncol. 2017 Apr 10;35(11):1154-1161. doi: 10.1200/JCO.2016.70.7091. Epub 2017 Feb 13.

20.

Effect of antithymocyte globulin source on outcomes of bone marrow transplantation for severe aplastic anemia.

Kekre N, Zhang Y, Zhang MJ, Carreras J, Ahmed P, Anderlini P, Atta EH, Ayas M, Boelens JJ, Bonfim C, Deeg HJ, Kapoor N, Lee JW, Nakamura R, Pulsipher MA, Eapen M, Antin JH.

Haematologica. 2017 Jul;102(7):1291-1298. doi: 10.3324/haematol.2017.164459. Epub 2017 Mar 24.

21.

Uncertainty of Physicians and Patients in Medical Decision Making.

Dhawale T, Steuten LM, Deeg HJ.

Biol Blood Marrow Transplant. 2017 Jun;23(6):865-869. doi: 10.1016/j.bbmt.2017.03.013. Epub 2017 Mar 14.

22.

Mutational analysis in serial marrow samples during azacitidine treatment in patients with post-transplant relapse of acute myeloid leukemia or myelodysplastic syndromes.

Woo J, Howard NP, Storer BE, Fang M, Yeung CC, Scott BL, Deeg HJ.

Haematologica. 2017 Jun;102(6):e216-e218. doi: 10.3324/haematol.2016.162909. Epub 2017 Feb 16. No abstract available.

23.

Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel.

de Witte T, Bowen D, Robin M, Malcovati L, Niederwieser D, Yakoub-Agha I, Mufti GJ, Fenaux P, Sanz G, Martino R, Alessandrino EP, Onida F, Symeonidis A, Passweg J, Kobbe G, Ganser A, Platzbecker U, Finke J, van Gelder M, van de Loosdrecht AA, Ljungman P, Stauder R, Volin L, Deeg HJ, Cutler C, Saber W, Champlin R, Giralt S, Anasetti C, Kröger N.

Blood. 2017 Mar 30;129(13):1753-1762. doi: 10.1182/blood-2016-06-724500. Epub 2017 Jan 17. Review.

24.

Massively parallel digital transcriptional profiling of single cells.

Zheng GX, Terry JM, Belgrader P, Ryvkin P, Bent ZW, Wilson R, Ziraldo SB, Wheeler TD, McDermott GP, Zhu J, Gregory MT, Shuga J, Montesclaros L, Underwood JG, Masquelier DA, Nishimura SY, Schnall-Levin M, Wyatt PW, Hindson CM, Bharadwaj R, Wong A, Ness KD, Beppu LW, Deeg HJ, McFarland C, Loeb KR, Valente WJ, Ericson NG, Stevens EA, Radich JP, Mikkelsen TS, Hindson BJ, Bielas JH.

Nat Commun. 2017 Jan 16;8:14049. doi: 10.1038/ncomms14049.

25.

Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.

Greenberg PL, Stone RM, Al-Kali A, Barta SK, Bejar R, Bennett JM, Carraway H, De Castro CM, Deeg HJ, DeZern AE, Fathi AT, Frankfurt O, Gaensler K, Garcia-Manero G, Griffiths EA, Head D, Horsfall R, Johnson RA, Juckett M, Klimek VM, Komrokji R, Kujawski LA, Maness LJ, O'Donnell MR, Pollyea DA, Shami PJ, Stein BL, Walker AR, Westervelt P, Zeidan A, Shead DA, Smith C.

J Natl Compr Canc Netw. 2017 Jan;15(1):60-87.

PMID:
28040720
26.

Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies.

Verstovsek S, Odenike O, Singer JW, Granston T, Al-Fayoumi S, Deeg HJ.

J Hematol Oncol. 2016 Dec 8;9(1):137.

27.

Factors Determining Responses to Azacitidine in Patients with Myelodysplastic Syndromes and Acute Myeloid Leukemia with Early Post-Transplantation Relapse: A Prospective Trial.

Woo J, Deeg HJ, Storer B, Yeung C, Fang M, Mielcarek M, Scott BL.

Biol Blood Marrow Transplant. 2017 Jan;23(1):176-179. doi: 10.1016/j.bbmt.2016.10.016. Epub 2016 Oct 24.

28.

Jumping translocations in myelodysplastic syndromes.

Yeung CCS, Deeg HJ, Pritchard C, Wu D, Fang M.

Cancer Genet. 2016 Sep;209(9):395-402. doi: 10.1016/j.cancergen.2016.08.002. Epub 2016 Aug 8.

29.

Response of Steroid-Refractory Acute GVHD to α1-Antitrypsin.

Marcondes AM, Hockenbery D, Lesnikova M, Dinarello CA, Woolfrey A, Gernsheimer T, Loghman-Adham M, Gelmont D, Storer B, Hansen JA, Deeg HJ.

Biol Blood Marrow Transplant. 2016 Sep;22(9):1596-1601. doi: 10.1016/j.bbmt.2016.05.011. Epub 2016 May 17.

30.

Consensus Opinion on Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis.

Ustun C, Gotlib J, Popat U, Artz A, Litzow M, Reiter A, Nakamura R, Kluin-Nelemans HC, Verstovsek S, Gajewski J, Perales MA, George T, Shore T, Sperr W, Saber W, Kota V, Yavuz AS, Pullarkat V, Rogosheske J, Hogan W, Van Besien K, Hagglund H, Damaj G, Arock M, Horny HP, Metcalfe DD, Deeg HJ, Devine S, Weisdorf D, Akin C, Valent P.

Biol Blood Marrow Transplant. 2016 Aug;22(8):1348-1356. doi: 10.1016/j.bbmt.2016.04.018. Epub 2016 Apr 27. No abstract available.

31.

Minimal Identifiable Disease and the Role of Conditioning Intensity in Hematopoietic Cell Transplantation for Myelodysplastic Syndrome and Acute Myelogenous Leukemia Evolving from Myelodysplastic Syndrome.

Festuccia M, Deeg HJ, Gooley TA, Baker K, Wood BL, Fang M, Sandmaier BM, Scott BL.

Biol Blood Marrow Transplant. 2016 Jul;22(7):1227-1233. doi: 10.1016/j.bbmt.2016.03.029. Epub 2016 Apr 6.

32.

Disruption of Iron Regulation after Radiation and Donor Cell Infusion.

Karoopongse E, Marcondes AM, Yeung C, Holman Z, Kowdley KV, Campbell JS, Deeg HJ.

Biol Blood Marrow Transplant. 2016 Jul;22(7):1173-1181. doi: 10.1016/j.bbmt.2016.03.031. Epub 2016 Apr 7.

33.

Cyclophosphamide conditioning in patients with severe aplastic anaemia given unrelated marrow transplantation: a phase 1-2 dose de-escalation study.

Anderlini P, Wu J, Gersten I, Ewell M, Tolar J, Antin JH, Adams R, Arai S, Eames G, Horwitz ME, McCarty J, Nakamura R, Pulsipher MA, Rowley S, Leifer E, Carter SL, DiFronzo NL, Horowitz MM, Confer D, Deeg HJ, Eapen M.

Lancet Haematol. 2015 Sep;2(9):e367-75. doi: 10.1016/S2352-3026(15)00147-7. Epub 2015 Sep 2.

34.

Phase II study of tosedostat with cytarabine or decitabine in newly diagnosed older patients with acute myeloid leukaemia or high-risk MDS.

Mawad R, Becker PS, Hendrie P, Scott B, Wood BL, Dean C, Sandhu V, Deeg HJ, Walter R, Wang L, Myint H, Singer JW, Estey E, Pagel JM.

Br J Haematol. 2016 Jan;172(2):238-45. doi: 10.1111/bjh.13829. Epub 2015 Nov 16.

PMID:
26568032
35.

A novel retroviral mutagenesis screen identifies prognostic genes in RUNX1 mediated myeloid leukemogenesis.

Rae DT, Hocum JD, Bii V, Deeg HJ, Trobridge GD.

Oncotarget. 2015 Oct 13;6(31):30664-74. doi: 10.18632/oncotarget.5133.

36.

Hematopoietic Cell Transplantation as Curative Therapy for Patients with Myelofibrosis: Long-Term Success in all Age Groups.

Deeg HJ, Bredeson C, Farnia S, Ballen K, Gupta V, Mesa RA, Popat U, Hari P, Saber W, Seftel M, Tamari R, Petersdorf EW.

Biol Blood Marrow Transplant. 2015 Nov;21(11):1883-7. doi: 10.1016/j.bbmt.2015.09.005. Epub 2015 Sep 11. Review.

37.

In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs.

Tefferi A, Kantarjian H, Rajkumar SV, Baker LH, Abkowitz JL, Adamson JW, Advani RH, Allison J, Antman KH, Bast RC Jr, Bennett JM, Benz EJ Jr, Berliner N, Bertino J, Bhatia R, Bhatia S, Bhojwani D, Blanke CD, Bloomfield CD, Bosserman L, Broxmeyer HE, Byrd JC, Cabanillas F, Canellos GP, Chabner BA, Chanan-Khan A, Cheson B, Clarkson B, Cohn SL, Colon-Otero G, Cortes J, Coutre S, Cristofanilli M, Curran WJ Jr, Daley GQ, DeAngelo DJ, Deeg HJ, Einhorn LH, Erba HP, Esteva FJ, Estey E, Fidler IJ, Foran J, Forman S, Freireich E, Fuchs C, George JN, Gertz MA, Giralt S, Golomb H, Greenberg P, Gutterman J, Handin RI, Hellman S, Hoff PM, Hoffman R, Hong WK, Horowitz M, Hortobagyi GN, Hudis C, Issa JP, Johnson BE, Kantoff PW, Kaushansky K, Khayat D, Khuri FR, Kipps TJ, Kripke M, Kyle RA, Larson RA, Lawrence TS, Levine R, Link MP, Lippman SM, Lonial S, Lyman GH, Markman M, Mendelsohn J, Meropol NJ, Messinger Y, Mulvey TM, O'Brien S, Perez-Soler R, Pollock R, Prchal J, Press O, Radich J, Rai K, Rosenberg SA, Rowe JM, Rugo H, Runowicz CD, Sandmaier BM, Saven A, Schafer AI, Schiffer C, Sekeres MA, Silver RT, Siu LL, Steensma DP, Stewart FM, Stock W, Stone R, Storb R, Strong LC, Tallman MS, Thompson M, Ueno NT, Van Etten RA, Vose JM, Wiernik PH, Winer EP, Younes A, Zelenetz AD, LeMaistre CA.

Mayo Clin Proc. 2015 Aug;90(8):996-1000. doi: 10.1016/j.mayocp.2015.06.001. Epub 2015 Jul 23. No abstract available.

38.

Therapy for Hematologic Cancers in Older Patients, Quality of Life, and Health Economics: Difficult Decisions.

Deeg HJ, Steuten LM.

JAMA Oncol. 2015 Aug;1(5):571-2. doi: 10.1001/jamaoncol.2015.1084. No abstract available.

PMID:
26181003
39.

Severe Refractory Immune Thrombocytopenia Successfully Treated with High-Dose Pulse Cyclophosphamide and Eltrombopag.

Anwer F, Yun S, Nair A, Ahmad Y, Krishnadashan R, Deeg HJ.

Case Rep Hematol. 2015;2015:583451. doi: 10.1155/2015/583451. Epub 2015 Jun 9.

40.

Treatment of refractory ITP and Evans syndrome by haematopoietic cell transplantation: is it indicated, and for whom?

Vaughn JE, Anwer F, Deeg HJ.

Vox Sang. 2016 Jan;110(1):5-11. doi: 10.1111/vox.12314. Epub 2015 Jul 14. Review.

41.

Second Allogeneic Hematopoietic Cell Transplantation for Patients with Fanconi Anemia and Bone Marrow Failure.

Ayas M, Eapen M, Le-Rademacher J, Carreras J, Abdel-Azim H, Alter BP, Anderlini P, Battiwalla M, Bierings M, Buchbinder DK, Bonfim C, Camitta BM, Fasth AL, Gale RP, Lee MA, Lund TC, Myers KC, Olsson RF, Page KM, Prestidge TD, Radhi M, Shah AJ, Schultz KR, Wirk B, Wagner JE, Deeg HJ.

Biol Blood Marrow Transplant. 2015 Oct;21(10):1790-5. doi: 10.1016/j.bbmt.2015.06.012. Epub 2015 Jun 23.

42.

Treatment ethics, quality of life and health economics in the management of hematopoietic malignancies in older patients.

Deeg HJ.

Bone Marrow Transplant. 2015 Sep;50(9):1145-9. doi: 10.1038/bmt.2015.130. Epub 2015 Jun 8. Review.

PMID:
26052908
43.

Hematopoietic cell transplantation for myelodysplastic syndrome.

Deeg HJ.

Am Soc Clin Oncol Educ Book. 2015:e375-80. doi: 10.14694/EdBook_AM.2015.35.e375. Review.

44.

SRSF2 Mutations Contribute to Myelodysplasia by Mutant-Specific Effects on Exon Recognition.

Kim E, Ilagan JO, Liang Y, Daubner GM, Lee SC, Ramakrishnan A, Li Y, Chung YR, Micol JB, Murphy ME, Cho H, Kim MK, Zebari AS, Aumann S, Park CY, Buonamici S, Smith PG, Deeg HJ, Lobry C, Aifantis I, Modis Y, Allain FH, Halene S, Bradley RK, Abdel-Wahab O.

Cancer Cell. 2015 May 11;27(5):617-30. doi: 10.1016/j.ccell.2015.04.006.

45.

Relapse after Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndromes: Analysis of Late Relapse Using Comparative Karyotype and Chromosome Genome Array Testing.

Yeung CCS, Gerds AT, Fang M, Scott BL, Flowers MED, Gooley T, Deeg HJ.

Biol Blood Marrow Transplant. 2015 Sep;21(9):1565-1575. doi: 10.1016/j.bbmt.2015.04.024. Epub 2015 May 4.

46.

Quantitative analysis of glycans, related genes, and proteins in two human bone marrow stromal cell lines using an integrated strategy.

Li X, Li D, Pang X, Yang G, Deeg HJ, Guan F.

Exp Hematol. 2015 Sep;43(9):760-9.e7. doi: 10.1016/j.exphem.2015.04.009. Epub 2015 May 1.

47.

Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis.

Kröger N, Giorgino T, Scott BL, Ditschkowski M, Alchalby H, Cervantes F, Vannucchi A, Cazzola M, Morra E, Zabelina T, Maffioli M, Pereira A, Beelen D, Deeg HJ, Passamonti F.

Blood. 2015 May 21;125(21):3347-50; quiz 3364. doi: 10.1182/blood-2014-10-608315. Epub 2015 Mar 17.

48.

Myelodysplastic syndromes, version 2.2015.

Greenberg PL, Stone RM, Bejar R, Bennett JM, Bloomfield CD, Borate U, De Castro CM, Deeg HJ, DeZern AE, Fathi AT, Frankfurt O, Gaensler K, Garcia-Manero G, Griffiths EA, Head D, Klimek V, Komrokji R, Kujawski LA, Maness LJ, O'Donnell MR, Pollyea DA, Scott B, Shami PJ, Stein BL, Westervelt P, Wheeler B, Shead DA, Smith C; National comprehensive cancer network.

J Natl Compr Canc Netw. 2015 Mar;13(3):261-72.

49.

Reevaluation of the pretransplant assessment of mortality score after allogeneic hematopoietic transplantation.

Au BK, Gooley TA, Armand P, Fang M, Madtes DK, Sorror ML, Boeckh MJ, Gibson CJ, Deeg HJ, Storb R, Appelbaum FR, Chien JW, Martin PJ.

Biol Blood Marrow Transplant. 2015 May;21(5):848-54. doi: 10.1016/j.bbmt.2015.01.011. Epub 2015 Jan 31.

50.

Role of hematopoietic stem cell transplantation in patients with myeloproliferative disease.

Salit RB, Deeg HJ.

Hematol Oncol Clin North Am. 2014 Dec;28(6):1023-35. doi: 10.1016/j.hoc.2014.08.003. Epub 2014 Oct 3. Review.

Supplemental Content

Support Center